Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Pirenzepine (WST-057) in Type 2 Diabetic Peripheral Neuropathy
NCT04005287Phase 2Completed
- Sponsor
- WinSanTor Inc.
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pirenzepine in diabetic peripheral neuropathy (DPN) (4 arms), sponsored by WinSanTor Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events as assessed by hematology and clinical pathology blood tests at 24 weeks, Incidence of Treatment-Emergent Adverse Events as assessed by vital signs at 24 weeks and 2 more. Started Oct 2019; status: completed.
02
Drugs
pirenzepine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04005287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005287.